Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
North Shore Long Island Jewish Health System National Alliance for Research on Schizophrenia and Depression |
---|---|
Information provided by: | North Shore Long Island Jewish Health System |
ClinicalTrials.gov Identifier: | NCT00790738 |
This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.
Condition | Intervention | Phase |
---|---|---|
Depression Bipolar Disorder |
Drug: Liothyronine (T3) Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression |
Estimated Enrollment: | 42 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
liothyronine (T3)
|
Drug: Liothyronine (T3)
liothyronine (T3) up to 50 micrograms a day
|
2: Placebo Comparator
placebo
|
Drug: placebo
placebo
|
Bipolar affective disorder is a debilitating illness, and is characterized by depression episodes that dominates the longitudinal course and are most difficult to treat. Controlled trials with monotherapy mood stabilizers such as lithium and valproate show little to no efficacy and antidepressants may offer no additional efficacy.
Recently there has been a growing interest in the use of quetiapine in bipolar depression. However, a successful treatment may take up to 8 weeks, and full remission is achieved in only 50% of patients. Thyroid hormone augmentation strategies have been used in unipolar depression with good results, but there is a paucity of its efficacy in bipolar depression (BD). To our knowledge there are no controlled studies regarding the efficacy of thyroid augmentation in BD. The present study proposes to evaluate the efficacy of T3 as an augmentation to treatment as usual in the treatment of BD. We plan to enroll patients with bipolar disorder I or II who are currently presenting with depressive symptoms. Patients will be randomized to 2 groups - liothyronine or placebo Results will provide information on the possible role of thyroid hormone augmentation in the treatment of patients with bipolar depression, and may contribute to alleviate the burden of this disabling condition.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Anu Tyagi | (718) 470- 8146 | atyagi@nshs.edu |
Contact: Raphael J Braga, MD | (718) 470-4801 | rbraga@nshs.edu |
United States, New York | |
The Zucker Hillside Hospital | Recruiting |
Glen Oaks, New York, United States, 11004 | |
Contact: Anu Tyagi 718-470-8146 | |
Principal Investigator: Raphael J Braga, MD |
Principal Investigator: | Raphael J Braga, MD | The Zucker Hillside Hospital, North Shore - LIJHS |
Responsible Party: | The Zucker Hillside Hospital - North Shore LIJ Health System ( Raphael J Braga, MD ) |
Study ID Numbers: | 08-001 |
Study First Received: | November 10, 2008 |
Last Updated: | August 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00790738 History of Changes |
Health Authority: | United States: Institutional Review Board |
bipolar disorder depression treatment randomized controlled trial |
Affective Disorders, Psychotic Depression Mental Disorders Bipolar Disorder |
Mood Disorders Psychotic Disorders Depressive Disorder Behavioral Symptoms |
Affective Disorders, Psychotic Depression Mental Disorders Bipolar Disorder |
Mood Disorders Depressive Disorder Behavioral Symptoms |